{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:45:56Z","timestamp":1774046756414,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health, Czech Republic","award":["NV19-03-00007"],"award-info":[{"award-number":["NV19-03-00007"]}]},{"name":"Ministry of Health, Czech Republic","award":["NV19-03-00007"],"award-info":[{"award-number":["NV19-03-00007"]}]},{"name":"Ministry of Health, Czech Republic","award":["NV19-03-00007"],"award-info":[{"award-number":["NV19-03-00007"]}]},{"name":"Ministry of Health, Czech Republic","award":["NV19-03-00007"],"award-info":[{"award-number":["NV19-03-00007"]}]},{"name":"Ministry of Health, Czech Republic","award":["NV19-03-00007"],"award-info":[{"award-number":["NV19-03-00007"]}]},{"name":"Ministry of Health, Czech Republic","award":["NV19-03-00007"],"award-info":[{"award-number":["NV19-03-00007"]}]},{"name":"Ministry of Health, Czech Republic","award":["NV19-03-00007"],"award-info":[{"award-number":["NV19-03-00007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>IMP2 and IMP3 are mRNA binding proteins involved in carcinogenesis. We examined a large cohort of ovarian tumors with the aim to assess the value of IMP2 and IMP3 for differential diagnosis, and to assess their prognostic significance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Immunohistochemical analyses with antibodies against IMP2 and IMP3 were performed on 554 primary ovarian tumors including 114 high grade serous carcinomas, 100 low grade serous carcinomas, 124 clear cell carcinomas, 54 endometrioid carcinomas, 34 mucinous carcinomas, 75 mucinous borderline tumors, and 41 serous borderline tumors (micropapillary variant). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher\u2019s Exact test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found IMP2 expression (in more than 5% of tumor cells) in nearly all cases of all tumor types, so the prognostic meaning could not be analyzed. The positive IMP3 expression (in more than 5% of tumor cells) was most common in mucinous carcinomas (82%) and mucinous borderline tumors (81%), followed by high grade serous (67%) and clear cell carcinomas (67%). The expression was less frequent in endometrioid carcinomas (39%), low grade serous carcinomas (23%), and micropapillary variant of serous borderline tumors (20%). Prognostic significance of IMP3 could be evaluated only in low grade serous carcinomas in the case of relapse-free survival, where negative cases showed better RFS (<jats:italic>p<\/jats:italic>\u00a0=\u20090.033).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Concerning differential diagnosis our results imply that despite the differences in expression in the different ovarian tumor types, the practical value for diagnostic purposes is limited. Contrary to other solid tumors, we did not find prognostic significance of IMP3 in ovarian cancer, with the exception of RFS in low grade serous carcinomas. However, the high expression of IMP2 and IMP3 could be of predictive value in ovarian carcinomas since IMP proteins are potential therapeutical targets.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-023-01300-4","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T04:31:48Z","timestamp":1675657908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-9320","authenticated-orcid":false,"given":"Krist\u00fdna","family":"N\u011bmejcov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela Kendall","family":"B\u00e1rt\u016f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romana","family":"Mich\u00e1lkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Drozenov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwole","family":"Fadare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Hausnerov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Laco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoslav","family":"Mat\u011bj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"M\u00e9hes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveena","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Stolnicu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"\u0160kapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00e1n","family":"\u0160vajdler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Stru\u017einsk\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Kocian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigurd F.","family":"Lax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Glenn","family":"McCluggage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Dundr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"issue":"7","key":"1300_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7):918\u201331.","journal-title":"Hum Pathol"},{"issue":"3","key":"1300_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/his.13248","volume":"71","author":"N Singh","year":"2017","unstructured":"Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathology. 2017;71(3):339\u201356.","journal-title":"Histopathology."},{"issue":"4","key":"1300_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/PGP.0000000000000530","volume":"38","author":"M Kobel","year":"2019","unstructured":"Kobel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, et al. Ovarian carcinoma Histotype: strengths and limitations of integrating morphology with Immunohistochemical predictions. Int J Gynecol Pathol. 2019;38(4):353\u201362.","journal-title":"Int J Gynecol Pathol"},{"issue":"5","key":"1300_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","volume":"35","author":"M Kobel","year":"2016","unstructured":"Kobel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An Immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430\u201341.","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"1300_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/his.13970","volume":"76","author":"WG McCluggage","year":"2020","unstructured":"McCluggage WG. Endometriosis-related pathology: a discussion of selected uncommon benign, premalignant and malignant lesions. Histopathology. 2020;76(1):76\u201392.","journal-title":"Histopathology."},{"issue":"2","key":"1300_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/PGP.0000000000000788","volume":"41","author":"S Rajendran","year":"2022","unstructured":"Rajendran S, McCluggage WG. WT1 positive ovarian Endometrioid tumors: observations from consult cases and strategies for distinguishing from serous neoplasms. Int J Gynecol Pathol. 2022;41(2):191\u2013202.","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"1300_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acschembio.1c00833","volume":"17","author":"C Dahlem","year":"2022","unstructured":"Dahlem C, Abuhaliema A, Kessler SM, Krohler T, Zoller BGE, Chanda S, et al. First small-molecule inhibitors targeting the RNA-binding protein IGF2BP2\/IMP2 for Cancer therapy. ACS Chem Biol. 2022;17(2):361\u201375.","journal-title":"ACS Chem Biol"},{"issue":"1","key":"1300_CR8","first-page":"3","volume":"39","author":"C Burdelski","year":"2018","unstructured":"Burdelski C, Jakani-Karimi N, Jacobsen F, M\u00f6ller-Koop C, Minner S, Simon R, et al. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: a tissue microarray study on 8,877 human cancers and normal tissues. Oncol Rep. 2018;39(1):3\u201312.","journal-title":"Oncol Rep"},{"issue":"3","key":"1300_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/PAP.0000000000000021","volume":"21","author":"Y Gong","year":"2014","unstructured":"Gong Y, Woda BA, Jiang Z. Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol. 2014;21(3):191\u2013200.","journal-title":"Adv Anat Pathol"},{"issue":"31","key":"1300_CR10","doi-asserted-by":"publisher","first-page":"49743","DOI":"10.18632\/oncotarget.10439","volume":"7","author":"A Barghash","year":"2016","unstructured":"Barghash A, Golob-Schwarzl N, Helms V, Haybaeck J, Kessler SM. Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2\/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma. Oncotarget. 2016;7(31):49743\u201350.","journal-title":"Oncotarget."},{"issue":"13","key":"1300_CR11","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.3390\/ijms20133204","volume":"20","author":"C Dahlem","year":"2019","unstructured":"Dahlem C, Barghash A, Puchas P, Haybaeck J, Kessler SM. The insulin-like growth factor 2 mRNA binding protein IMP2\/IGF2BP2 is overexpressed and correlates with poor survival in pancreatic Cancer. Int J Mol Sci. 2019;20(13):3204.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1300_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/cancers12010007","volume":"12","author":"M Xing","year":"2019","unstructured":"Xing M, Li P, Wang X, Li J, Shi J, Qin J, et al. Overexpression of p62\/IMP2 can promote cell migration in hepatocellular carcinoma via activation of the Wnt\/\u03b2-catenin pathway. Cancers. 2019;12(1):7.","journal-title":"Cancers."},{"issue":"1","key":"1300_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/cancers12010007","volume":"12","author":"M Xing","year":"2019","unstructured":"Xing M, Li P, Wang X, Li J, Shi J, Qin J, et al. Overexpression of p62\/IMP2 can promote cell migration in hepatocellular carcinoma via activation of the Wnt\/beta-catenin pathway. Cancers. 2019;12(1):7.","journal-title":"Cancers."},{"key":"1300_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.anndiagpath.2019.02.013","volume":"40","author":"SK Mohanty","year":"2019","unstructured":"Mohanty SK, Tiwari A, Singh C, Walsh C, Chuang F, Kim E, et al. High-grade ovarian serous carcinomas: significant correlation of histologic patterns with IMP3 and E-cadherin predicting disease recurrence and survival. Ann Diagn Pathol. 2019;40:30\u20139.","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"1300_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00428-022-03338-z","volume":"481","author":"P Dundr","year":"2022","unstructured":"Dundr P, Bazalova B, Bartu M, Bosse T, Drozenova J, Fabian P, et al. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance. Virchows Arch. 2022;481(2):201\u201312.","journal-title":"Virchows Arch"},{"issue":"6","key":"1300_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1309\/AJCPQDQXJ4FNRFQB","volume":"133","author":"P Mhawech-Fauceglia","year":"2010","unstructured":"Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol. 2010;133(6):899\u2013908.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"1300_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/his.12096","volume":"62","author":"P Mhawech-Fauceglia","year":"2013","unstructured":"Mhawech-Fauceglia P, Yan L, Liu S, Pejovic T. ER+ \/PR+ \/TFF3+ \/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology. 2013;62(7):976\u201385.","journal-title":"Histopathology."},{"issue":"1","key":"1300_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/PAI.0000000000000720","volume":"28","author":"A Zaidi","year":"2020","unstructured":"Zaidi A, Gupta P, Gupta N, Rajwanshi A, Rai B, Gainder S. Role of immunohistochemistry to distinguish grade 3 Endometrioid carcinoma and uterine serous carcinoma. Appl Immunohistochem Mol Morphol. 2020;28(1):42\u20138.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"1300_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/PAS.0b013e3181483ff8","volume":"32","author":"W Zheng","year":"2008","unstructured":"Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32(2):304\u201315.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1300_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1210\/jc.2018-00544","volume":"104","author":"M Li","year":"2019","unstructured":"Li M, Zhao H, Zhao SG, Wei DM, Zhao YR, Huang T, et al. The HMGA2-IMP2 pathway promotes Granulosa cell proliferation in polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(4):1049\u201359.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1300_CR21","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.humpath.2012.12.003","volume":"44","author":"O Fadare","year":"2013","unstructured":"Fadare O, Liang SX, Crispens MA, Jones HW 3rd, Khabele D, Gwin K, et al. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol. 2013;44(8):1508\u201315.","journal-title":"Hum Pathol"},{"issue":"12","key":"1300_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/modpathol.3800960","volume":"20","author":"C Li","year":"2007","unstructured":"Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007;20(12):1263\u20138.","journal-title":"Mod Pathol"},{"issue":"2","key":"1300_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.21873\/anticanres.11351","volume":"37","author":"A El-Balat","year":"2017","unstructured":"El-Balat A, S\u00e4nger N, Karn T, Becker S, Holtrich U, Muallem Z, et al. IMP3 expression in borderline tumors of the ovary. Anticancer Res. 2017;37(2):583\u20138.","journal-title":"Anticancer Res"},{"issue":"10","key":"1300_CR24","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.humpath.2015.06.002","volume":"46","author":"H Imamura","year":"2015","unstructured":"Imamura H, Ohishi Y, Aman M, Shida K, Shinozaki T, Yasutake N, et al. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor. Hum Pathol. 2015;46(10):1455\u201363.","journal-title":"Hum Pathol"},{"issue":"3","key":"1300_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/modpathol.2008.206","volume":"22","author":"M K\u00f6bel","year":"2009","unstructured":"K\u00f6bel M, Xu H, Bourne PA, Spaulding BO, Shih Ie M, Mao TL, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 2009;22(3):469\u201375.","journal-title":"Mod Pathol"},{"issue":"8","key":"1300_CR26","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.prp.2018.05.026","volume":"214","author":"L Lu","year":"2018","unstructured":"Lu L, Wang S, Zhu Q, Qu Y, Gu W, Ning Y, et al. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes. Pathol Res Pract. 2018;214(8):1087\u201394.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"1300_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/PGP.0b013e318189a724","volume":"28","author":"A Noske","year":"2009","unstructured":"Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, et al. IMP3 expression in human ovarian cancer is associated with improved survival. Int J Gynecol Pathol. 2009;28(3):203\u201310.","journal-title":"Int J Gynecol Pathol"},{"issue":"9","key":"1300_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/PAI.0000000000000021","volume":"22","author":"M Chist\u00e9","year":"2014","unstructured":"Chist\u00e9 M, Alexis J, Recine M. IMP3 expression in serous tumors of the ovary. Appl Immunohistochem Mol Morphol. 2014;22(9):658\u201362.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"1300_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/PGP.0b013e31826ddc4e","volume":"32","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Garcia-Buitrago MT, Koru-Sengul T, Schuman S, Ganjei-Azar P. An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas. Int J Gynecol Pathol. 2013;32(5):476\u201381.","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"1300_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13046-014-0060-2","volume":"33","author":"Y Wang","year":"2014","unstructured":"Wang Y, Li L, Wang Y, Yuan Z, Zhang W, Hatch KD, et al. IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis. J Exp Clin Cancer Res. 2014;33(1):60.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"1300_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/bjc.2015.254","volume":"113","author":"KF Hsu","year":"2015","unstructured":"Hsu KF, Shen MR, Huang YF, Cheng YM, Lin SH, Chow NH, et al. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer. 2015;113(3):414\u201324.","journal-title":"Br J Cancer"},{"key":"1300_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13000-016-0467-5","volume":"11","author":"R Bi","year":"2016","unstructured":"Bi R, Shen X, Zhang W, Cheng Y, Feng Z, Cai X, et al. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression. Diagn Pathol. 2016;11:17.","journal-title":"Diagn Pathol"},{"issue":"7","key":"1300_CR33","first-page":"3387","volume":"9","author":"Q Zhu","year":"2017","unstructured":"Zhu Q, Qu Y, Zhang Q, Lu L, Weng W, Zhang H, et al. IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression. Am J Transl Res. 2017;9(7):3387\u201398.","journal-title":"Am J Transl Res"},{"issue":"12","key":"1300_CR34","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1016\/j.humpath.2014.06.031","volume":"45","author":"M Santacana","year":"2014","unstructured":"Santacana M, Maiques O, Valls J, Gatius S, Ab\u00f3 AI, L\u00f3pez-Garc\u00eda M, et al. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Hum Pathol. 2014;45(12):2394\u2013403.","journal-title":"Hum Pathol"},{"issue":"6","key":"1300_CR35","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/PAS.0b013e318219c6f9","volume":"35","author":"L Zhang","year":"2011","unstructured":"Zhang L, Liu Y, Hao S, Woda BA, Lu D. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas. Am J Surg Pathol. 2011;35(6):868\u201372.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"1300_CR36","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/PAS.0b013e3182834d41","volume":"37","author":"T Takeuchi","year":"2013","unstructured":"Takeuchi T, Ohishi Y, Imamura H, Aman M, Shida K, Kobayashi H, et al. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma. Am J Surg Pathol. 2013;37(7):1091\u20139.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"1300_CR37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/bjc.2016.27","volume":"114","author":"K Hiramatsu","year":"2016","unstructured":"Hiramatsu K, Yoshino K, Serada S, Yoshihara K, Hori Y, Fujimoto M, et al. Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas. Br J Cancer. 2016;114(5):554\u201361.","journal-title":"Br J Cancer"},{"issue":"3","key":"1300_CR38","first-page":"671","volume":"24","author":"L Gu","year":"2004","unstructured":"Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol. 2004;24(3):671\u20138.","journal-title":"Int J Oncol"},{"issue":"1","key":"1300_CR39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13046-021-01994-8","volume":"40","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhao S, Tan C, Gu Y, He X, Du X, et al. RNA-binding protein IMP3 is a novel regulator of MEK1\/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA. J Exp Clin Cancer Res. 2021;40(1):200.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"1300_CR40","first-page":"10269","volume":"10","author":"LM Er","year":"2017","unstructured":"Er LM, Li Y, Wu ML, Li B, Tan BB, Gao Y, et al. Insulin-like growth factor II mRNA binding protein 3 regulates proliferation, invasion and migration of neuroendocrine cancer cells. Int J Clin Exp Pathol. 2017;10(10):10269\u201375.","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-023-01300-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-023-01300-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-023-01300-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T04:35:35Z","timestamp":1675658135000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-023-01300-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1186\/s13000-023-01300-4","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"16 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the General University Hospital in Prague in compliance with the Helsinki Declaration (No. 2140\/19\u2009S-IV). The Ethics Committee waived the requirement for informed consent as according to the Czech Law (Act. no. 373\/11, and its amendment Act no. 202\/17), it is not necessary to obtain informed consent in fully anonymized studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial and\/or non-financial interests relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}